Education
About Us
Working with TipRanks
Follow Us
Indivior PLC (INDV)
NASDAQ:INDV
INDV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.33 - $17.25
Previous CloseN/A
Volume129.08K
Average Volume (3M)2.29M
Market Cap
£2.14B
Enterprise Value$1.19B
Total Cash (Recent Filing)£510.00M
Total Debt (Recent Filing)£58.00M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Oct 23, 2025EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding124,769,530
10 Day Avg. Volume2,550,268
30 Day Avg. Volume2,291,123
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£18.34Price Target Upside-16.65% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial Performance1Q25 group results beat expectations, with group revenues declining a more modest 6% compared to consensus expectations of a 14% decline.
Market PositionSublocade retains a dominant market share with approximately 80% share within the cohort for buprenorphine-based LAI and 60% share of LAI-naive patients.
Operational EfficiencyThe company achieved significant opex savings, contributing to the group sales beat expectations by 9%, gross margin by 10%, and adj. EBIT by over 40%.
Bears Say
CompetitionSublocade was ultimately $100M below initial 2024 guidance from competitor Brixadi share gains and also CJS funding disruption.
Market ChallengesCJS funding gaps remain a key headwind, affecting Sublocade sales and contributing to a 38% decline in the CJS market.
Operational CostsAnalyst thinks INDV is overspending on G&A and the operational structure can be much more efficient.
Indivior News
INDV FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was $7.33 and its highest was $17.25 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is £2.14B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Oct 23, 2025 which is in 73 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Jul 31, 2025. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.26.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Overvalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 0.37.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 124,769,530 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of $0.51 in its last earnings report, beating expectations of $0.25. Following the earnings report the stock price went up 16.092%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in INDV
Indivior Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£18.34 (-16.65% Downside)
£18.34 (-16.65% Downside)
Blogger Sentiment
Bullish
INDV Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth £8.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.38%
Trailing 12-Months
Company Description
Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
INDV Stock 12 Month Forecast
Average Price Target
$18.34
▼(-16.65% Downside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
4.97% Insiders
3.60% Mutual Funds
<0.01% Other Institutional Investors
82.94% Public Companies and
Individual Investors